Finance

Lists
HNSPF:OTCMKTS
Hansoh Pharmaceutical Group Company Ltd
$4.61
0.00%
(0.00) 1D
Sep 3, 2:49:24 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HNSPF...
Mkt. cap
219.76B
Avg. vol.
975.00
Volume
0.00
52-wk high
$5.16
52-wk low
$3.82
Shares outstanding
6.06B
No. of employees
10K
Mkt. cap
219.76B
Avg. vol.
975.00
Volume
0.00
52-wk high
$5.16
52-wk low
$3.82
Shares outstanding
6.06B
No. of employees
10K
Profile
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company that manufactures and sells various types of medicine in mainland China. It was founded in 1995 in Lianyungang, Jiangsu Province, China, by Zhong Huijuan, who is the company's chair. Zhong and her family own 66% of the company. It is the largest psychotropic drug producer in China. Hansoh Pharmaceutical had an initial public offering on the main board of the Hong Kong Stock Exchange on 14 June 2019. In August 2022, it was announced that the company's stock would be added to the Hang Seng Index. Wikipedia
About Hansoh Pharmaceutical Group Company Ltd
CEO-
Employees9.64K
Founded1995
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.80B
3.80B
4.15B
4.15B
Cost of goods sold
420.88M
420.88M
336.81M
336.81M
Cost of revenue
420.88M
420.88M
336.81M
336.81M
Research and development expenses
958.57M
958.57M
869.69M
869.69M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.29B
1.29B
1.09B
1.09B
Operating expense
2.25B
2.25B
1.97B
1.97B
Total operating expenses
2.67B
2.67B
2.31B
2.31B
Operating income
1.12B
1.12B
1.84B
1.84B
Other non operating income
31.11M
31.11M
28.34M
28.34M
EBT including unusual items
1.43B
1.43B
2.50B
2.50B
EBT excluding unusual items
1.42B
1.42B
2.46B
2.46B
Income tax expense
220.95M
220.95M
375.70M
375.70M
Effective tax rate
15.44%
15.44%
15.00%
15.00%
Other operating expenses
6.65M
6.65M
9.48M
9.48M
Net income
1.21B
1.21B
2.13B
2.13B
Net profit margin
31.87%
31.87%
51.28%
51.28%
Earnings per share
-
-
-
-
Interest and investment income
284.14M
284.14M
630.79M
630.79M
Interest expense
-764.50K
-764.50K
-24.31M
-24.31M
Net interest expenses
283.37M
283.37M
606.48M
606.48M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.21B
1.21B
1.93B
1.93B
Gain or loss from assets sale
-1.70M
-1.70M
-
-
AI content may include mistakes. Learn more
Google apps